Published in:
01-01-2017 | Case Report
Vitamin D-mediated hypercalcemia in multicentric Castleman’s disease
Authors:
Ken-ichiro Tanaka, Ippei Kanazawa, Hitomi Miyake, Shozo Yano, Chika Amano, Noriyoshi Ishikawa, Riruke Maruyama, Toshitsugu Sugimoto
Published in:
Journal of Bone and Mineral Metabolism
|
Issue 1/2017
Login to get access
Abstract
Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disorder, which represents various symptoms caused by the hyperproduction of interleukin-6 (IL-6). However, case studies of MCD accompanied by hypercalcemia have rarely been reported thus far. A 78-year-old male had generalized fatigue, and his laboratory data revealed elevated serum calcium (Ca) and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels (11.5 mg/dl and 80 pg/ml, respectively), while the serum intact parathyroid hormone level was low (4 pg/ml). Computed tomography showed multicentric lymphadenopathy. The serum IL-6 level was elevated (20.7 pg/ml), and pathological examination of a supraclavicular lymph node specimen led us to diagnose MCD. Moreover, immunostaining analysis showed that vitamin D-activating enzyme 25-hydroxyvitamin D 1-alpha-hydroxylase was expressed in lymph node macrophages. Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)2D and IL-6. We first reported a case of vitamin D-mediated hypercalcemia in MCD.